Announced
Completed
Financials
Tags
Pharmaceuticals
Majority
Single Bidder
asset-light business model
Friendly
Completed
Cross Border
Private Equity
Acquisition
Private
United Kingdom
Synopsis
HIG Capital, an investment firm, completed the acquisition of a majority stake in Aspire Pharma, a provider of niche generic and branded specialty pharmaceuticals, for $298m. Juno Pharmaceuticals, a biopharmaceutical company, will divest its stake. “We are delighted to be supporting Graham and his team to further build upon Aspire’s success. The Company’s track record of identifying, developing and launching niche pharmaceutical products, coupled with H.I.G.’s international presence and history of supporting organic and acquisitive growth in its portfolio companies, underpins an exciting next chapter for Aspire,” John Harper, HIG Capital Managing Director.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.